Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

    ... treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA ...

    Research Article last updated 04/14/2017 - 9:09am.

  2. Management of lower-risk myelodysplastic syndromes without del5q: Current approach and future trends

    ... agents (ESAs), immunosuppressive therapy (IST), lenalidomide and hypomethylating agents (HMAs). We also discuss the ...

    Research Article last updated 03/22/2017 - 9:46am.

  3. Jane Massey’s Story

    ...   They decided to put me on an oral medication, lenalidomide (Revlimid®) and see if that helped my blood counts. Thus far ...

    Patient Chronicle last updated 04/11/2017 - 7:29am.

  4. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

    Journal Title:  Leukemia Primary Author:  Platzbecker U Author(s):  Platzbeck...

    Research Article last updated 02/04/2013 - 2:29pm.

  5. Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights

    ... harboring TP53 mutation do not show a good response to lenalidomide therapy. In general, the results of this study show that ...

    Research Article last updated 02/01/2017 - 8:15am.

  6. Treatment of low-risk myelodysplastic syndromes

    ... fails ESA treatment, the available options may include lenalidomide (approved for del5q positive cases), hypomethylating agents, ...

    Research Article last updated 01/26/2017 - 10:42am.

  7. Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure

    ... agents, including 5-azacytidine, deoxyazacytidine, and lenalidomide . For patients no longer benefitting from these agents, there ...

    Research Article last updated 01/26/2017 - 10:36am.

  8. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications

    ... manifested as erythroid hypoplasia. P53 antagonism by lenalidomide or other therapeutics such as antisense oligonucleotides, ...

    Research Article last updated 01/26/2017 - 10:06am.

  9. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

    ... for ESA- refractory or relapsed patients include lenalidomide , alone or in combination with ESAs; oral azacitidine ; ...

    Research Article last updated 12/09/2016 - 2:50pm.

  10. Recent developments in bone marrow transplants

    ... marrow transplantation. A prolonged course of lenalidomide (Revlimid, Celgene) maintenance following autologous ...

    Article last updated 11/16/2016 - 2:56pm.